United Nations: The delta version, significantly higher permeable tension of COVID-19, expected to become a “dominant lineage” if current trends continue WHO A warning has been issued after it was reported in 85 countries and it is continuing to be detected in more places around the world.
The COVID-19 weekly epidemiological update released by the World Health Organization (WHO) on June 22 states that globally, version alpha is reported in 170 countries, regions or regions, beta in 119 countries, gamma in 71 countries and Delta has been reported. country.
“The delta, which is now reported in 85 countries globally, is being reported in new countries across all WHO regions, 11 of which were reported in the past two weeks,” the update said.
The WHO said the four existing ‘variants of concern’ being closely monitored – alpha, beta, gamma and delta – are widespread and have been found in all WHO areas. “The Delta version is significantly more permeable than the Alpha version, and is expected to become a dominant lineage if current trends continue.”
The update said that India recorded the highest number of new Covid19 cases at 441,976 compared to the previous week (June 14-20, 2021), which is 30 percent less than the previous week. The highest number of new deaths were recorded from India (16,329 new deaths; 1.2 new deaths per 100,000; 31 percent decrease).
The Southeast Asia region recorded more than 600,000 new cases and more than 19,000 new deaths, a decrease of 21 percent and 26 percent compared to the previous week.
“The declining trend in weekly cases and deaths in the region is mainly linked to the decreasing incidence in India,” the update said.
The WHO notes that since the last detailed update on 8 June, new evidence has been published on the phenotypic characteristics of the delta variant. “A Singapore study showed that infection with the delta variant was associated with higher odds of oxygen requirement, intensive care unit (ICU) admission, or death,” it said.
In addition, a study in Japan “estimating the relative instantaneous reproduction number (a measure of transmission at a specific point in time) showed that the delta version was associated with greater transmittance than the alpha version”.
“The relative instantaneous reproduction numbers were estimated to be 1.56 for the Alpha and 1.78 for the Delta, when compared with the variants that circulated in Japan before December 2020. Overall, this study showed that Delta was associated with 1.23 times higher transmittance than Alpha,” said Update.
The update also noted two studies that have provided evidence of the effectiveness of the Pfizer BioNTech-Comirneti and AstraZeneca-Vaxjeveria vaccines against the delta variant. A study reports on the effectiveness of these vaccines against serious illness (hospitalization) caused by Delta in individuals over the age of 16. United Kingdom.
Vaccination The effectiveness against hospitalization due to the delta and alpha variants was estimated to be 96 percent and 95 percent, respectively, for Pfizer BioNTech-Comirneti and 92 percent and 86 percent, respectively, for AstraZeneca-Vaxjeveria, after the second dose at 14 days post-second dose. was imposed.
The single-dose effectiveness against hospitalization 21 days after vaccination for Pfizer BioNTech-comerneti was 94 percent against Delta and 83 percent against Alpha. The effectiveness of a single dose of AstraZeneca-Vaxjeveria against hospitalization was similar for the delta and alpha variants.
a second study from Scotland found that two doses of Pfizer BioNTech-Comirneti were 83 percent and 79 percent effective against symptomatic disease and infection caused by Delta, respectively, 14 days after receiving the second dose in individuals 15 years of age and older.
“Together, these studies suggest that VE is marginally reduced in preventing symptomatic disease and infection due to the delta variant compared to the alpha … the study supported both Pfizer BioNtech-Comerneti and AstraZeneca-Vaxjeveria.” There is also further evidence of the importance of the two doses in preventing hospitalization, symptomatic disease and infection due to both the delta and alpha forms,” the update said.
The COVID-19 weekly epidemiological update released by the World Health Organization (WHO) on June 22 states that globally, version alpha is reported in 170 countries, regions or regions, beta in 119 countries, gamma in 71 countries and Delta has been reported. country.
“The delta, which is now reported in 85 countries globally, is being reported in new countries across all WHO regions, 11 of which were reported in the past two weeks,” the update said.
The WHO said the four existing ‘variants of concern’ being closely monitored – alpha, beta, gamma and delta – are widespread and have been found in all WHO areas. “The Delta version is significantly more permeable than the Alpha version, and is expected to become a dominant lineage if current trends continue.”
The update said that India recorded the highest number of new Covid19 cases at 441,976 compared to the previous week (June 14-20, 2021), which is 30 percent less than the previous week. The highest number of new deaths were recorded from India (16,329 new deaths; 1.2 new deaths per 100,000; 31 percent decrease).
The Southeast Asia region recorded more than 600,000 new cases and more than 19,000 new deaths, a decrease of 21 percent and 26 percent compared to the previous week.
“The declining trend in weekly cases and deaths in the region is mainly linked to the decreasing incidence in India,” the update said.
The WHO notes that since the last detailed update on 8 June, new evidence has been published on the phenotypic characteristics of the delta variant. “A Singapore study showed that infection with the delta variant was associated with higher odds of oxygen requirement, intensive care unit (ICU) admission, or death,” it said.
In addition, a study in Japan “estimating the relative instantaneous reproduction number (a measure of transmission at a specific point in time) showed that the delta version was associated with greater transmittance than the alpha version”.
“The relative instantaneous reproduction numbers were estimated to be 1.56 for the Alpha and 1.78 for the Delta, when compared with the variants that circulated in Japan before December 2020. Overall, this study showed that Delta was associated with 1.23 times higher transmittance than Alpha,” said Update.
The update also noted two studies that have provided evidence of the effectiveness of the Pfizer BioNTech-Comirneti and AstraZeneca-Vaxjeveria vaccines against the delta variant. A study reports on the effectiveness of these vaccines against serious illness (hospitalization) caused by Delta in individuals over the age of 16. United Kingdom.
Vaccination The effectiveness against hospitalization due to the delta and alpha variants was estimated to be 96 percent and 95 percent, respectively, for Pfizer BioNTech-Comirneti and 92 percent and 86 percent, respectively, for AstraZeneca-Vaxjeveria, after the second dose at 14 days post-second dose. was imposed.
The single-dose effectiveness against hospitalization 21 days after vaccination for Pfizer BioNTech-comerneti was 94 percent against Delta and 83 percent against Alpha. The effectiveness of a single dose of AstraZeneca-Vaxjeveria against hospitalization was similar for the delta and alpha variants.
a second study from Scotland found that two doses of Pfizer BioNTech-Comirneti were 83 percent and 79 percent effective against symptomatic disease and infection caused by Delta, respectively, 14 days after receiving the second dose in individuals 15 years of age and older.
“Together, these studies suggest that VE is marginally reduced in preventing symptomatic disease and infection due to the delta variant compared to the alpha … the study supported both Pfizer BioNtech-Comerneti and AstraZeneca-Vaxjeveria.” There is also further evidence of the importance of the two doses in preventing hospitalization, symptomatic disease and infection due to both the delta and alpha forms,” the update said.
.